Literature DB >> 22272651

Stromal responses to fractionated radiotherapy.

Muqeem A Qayyum1, Michael F Insana.   

Abstract

PURPOSE: Recently, several landmark randomized trials were published that justify the use of alternative fractionation schemes, e.g., hypofractionation, in adjuvant applications of whole-breast radiotherapy following breast-conserving surgery. We are studying effects of fractionated photon radiotherapy on stromal cell biology to understand how fractionation parameters influence the cellular microenvironment. METHODS AND MATERIALS: Three-dimensional (3-D) collagen matrices, fibroblasts, and transforming growth factor beta 1 (TGF-β1) were combined to model microenvironmental components of mammary stroma. We explored the effects of fractionation schemes on collagen matrix stiffness and fibroblast activation using this culture model. Samples were exposed to 6 MV X-rays from a linear accelerator in daily fraction sizes of 90, 180 and 360 cGy over three days in a manner consistent with irradiation exposure during radiotherapy.
RESULTS: Fibroblast-cell activation and collagen sample stiffness both increased over time for all samples, but marked changes were noted when samples were irradiated and/or stimulated with growth factors in relation to the magnitude of the stimulus. We found a significant reduction in fibroblast proliferation and activation with fraction size but a modest and irreversible increase in matrix stiffness as the dose increased. Overall, larger fraction sizes reduced conditions leading to the formation of a reactive stroma.
CONCLUSION: There is a significant reduction in fibroblast activation and a modest increase in matrix stiffness with increasing fraction size over a 72-hour observation time in 3-D cultures modeling mammary stroma. However, expanded in vitro studies with more mammary components are needed to evaluate the net effects of stromal reactivity to radiotherapy. Our results suggest that the stromal cell microenvironment is an important consideration when optimizing fractionation schedules.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22272651     DOI: 10.3109/09553002.2012.660301

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  6 in total

1.  Shear Wave Elastography Can Differentiate between Radiation-Responsive and Non-responsive Pancreatic Tumors: An ex Vivo Study with Murine Models.

Authors:  Hexuan Wang; Bradley Mills; Reem Mislati; Rifat Ahmed; Scott A Gerber; David Linehan; Marvin M Doyley
Journal:  Ultrasound Med Biol       Date:  2019-11-11       Impact factor: 2.998

Review 2.  Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma.

Authors:  Thomas Lambin; Cyril Lafon; Robert Andrew Drainville; Mathieu Pioche; Frédéric Prat
Journal:  World J Gastroenterol       Date:  2022-04-07       Impact factor: 5.374

3.  Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.

Authors:  Charles E Rutter; Kimberly L Johung; Xiaopan Yao; Alex Y Lu; Lucia B Jilaveanu; James B Yu; Joseph N Contessa; Harriet M Kluger; Veronica L S Chiang; Ranjit S Bindra
Journal:  J Radiosurg SBRT       Date:  2016

4.  Stromal-epithelial responses to fractionated radiotherapy in a breast cancer microenvironment.

Authors:  Muqeem A Qayyum; Jin Tae Kwak; Michael F Insana
Journal:  Cancer Cell Int       Date:  2015-06-27       Impact factor: 5.722

Review 5.  Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies.

Authors:  Go J Yoshida; Arata Azuma; Yukiko Miura; Akira Orimo
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 6.  The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.

Authors:  Kimberly M Arnold; Nicole J Flynn; Adam Raben; Lindsay Romak; Yan Yu; Adam P Dicker; Firas Mourtada; Jennifer Sims-Mourtada
Journal:  Cancer Growth Metastasis       Date:  2018-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.